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Introduction
Guidelines for the management of cardiovascular risk
factors1–3 and diseases4,5 have been well established,
based on massive series of randomized control trials
that showed significant impact on cardiovascular
outcomes. Therefore, it is generally agreed that the
major barrier to effective cardiovascular prevention is
not the lack of evidence but the lack of motivation to
follow the guidelines.6–8 It remains true that strict
performance of the guidelines may improve the
outcomes of stable patients with cardiovascular risk
factors and/or diseases.7
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Methods: A total of 124 outpatients randomly selected from 586 stable outpatients on regular visits to the same
senior cardiologist were invited to receive measurements of brachial-ankle pulse wave velocity (baPWV) and ankle-
brachial index (ABI) using a novel device during their clinic visits. Abnormally high baPWV was defined using the
age- and sex-stratified reference ranges obtained from a previous community survey.
Results: The prevalence of high baPWV in the studied outpatients was 24.2% and the prevalence of low ABI
(< 0.9) was 8.1%. Based on the reports of baPWV and ABI at the point of care, medications were adjusted in
56 patients (45.2%). In 22 patients who had adjusted antihypertensive medication and repeat examinations of
baPWV and ABI at subsequent visits, systolic blood pressure fell by 11 mmHg (p = 0.012), and baPWV fell by
0.2 m/s (p = 0.001).
Conclusion: Abnormal baPWV and ABI are not uncommon in stable patients who are regularly followed up at a cardiology
clinic where treatment guidelines are completely followed. Fast assessment of arteriosclerosis and atherosclerosis
at the point of care may provide better care for this group of patients. [J Chin Med Assoc 2006;69(1):14–20]
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Arteriosclerosis,9 or arterial stiffening,10 and
atherosclerosis11 are the 2 major underlying
pathophysiologies of arterial disease and the primary
cause of cardiovascular disease. Both arteriosclerosis9
and atherosclerosis11 are markers for future
cardiovascular events and are also targets for preventive
intervention.12,13 Pulse wave velocity (PWV) along an
arterial segment has been used to assess the extent of
arterial stiffening for decades.14 Ankle-brachial index
(ABI), a simple ratio of the systolic blood pressure over
the ankle and arm, is a well-recognized index reflecting
the extent of atherosclerosis in the coronary and
noncoronary arterial beds.15 It appears reasonable to
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speculate that strict adherence to cardiovascular
treatment guidelines for stable patients being long-
term followed up would improve arteriosclerosis and
atherosclerosis to an extent comparable with that in
the low-risk population. Therefore, the present study
investigated the prevalence of arteriosclerosis and
atherosclerosis in stable patients and explored the
potential for better care.
Methods
Study population
A senior cardiologist (C.H.C.) at the Taipei Veterans
General Hospital regularly cared for about 60 patients
during an outpatient clinic service 3 times a week,
prior to the beginning of the study. Among these
outpatients, about 10 were new patients on their first
visit and 50 were stable patients who had documented
chronic cardiovascular diseases and were receiving
regular long-term (> 1 year) care at the outpatient
clinic. Therefore, the stable patients had paid in total
about 600 (50 = 3 = 4 weeks) visits to the same
cardiologist. Standard guidelines at the clinic were
directed towards the treatment of: hypertension,1 high
blood cholesterol,3 diabetes mellitus,16 and chronic
heart failure.17 The study was conducted in 12
consecutive cardiology clinic services in 4 weeks. During
each study clinic service, 1 of every 5 patients, according
to the actual order of entering the clinic office, was
offered a free examination of baPWV and ABI, if he or
she was not a new patient. The selected patients were
guided to another room nearby for examination and
returned to the clinic office about 20 minutes later
with the report for interpretation and further
management. About 10 patients were selected in a
clinic service session and, in total, 124 patients were
selected from a total of 586 stable patients in the 12
study clinic services. Medical diagnosis, personal history,
and prescription of cardiovascular medications were
recorded in a case report form for all 586 stable
patients.
Assessment of arteriosclerosis and atherosclerosis
The measurements of baPWV and ABI were performed
using a novel device (VP-1000; Colin Corporation,
Komaki, Japan) with well-documented validity and
reproducibility.18 Personal data, including identification
number, date of birth, height, and weight were entered
through the front panel of the device while participants
were resting in the supine position. Pneumatic pressure
cuffs were placed snugly around both arms and both
ankles. Electrocardiographic electrodes were attached
on  bo th  wr i s t s ,  and  a  m i c rophone  fo r
phonocardiography was placed at the second intercostal
space at the left margin of the sternum. After completion
of the preparation, the fully automatic data acquisition
and processing procedure started with the simultaneous
measurements of blood pressure over the 4 extremities
by the oscillometric principle, followed by pulse volume
recording over the right arm and both ankles for 10
seconds when the cuff pressures were maintained at a
level of 60 mmHg. The recorded cuff pressure signals
during pulse volume recording are known as the pulse
volume traces and have been found to correspond to
the intra-arterial pressure contours.19 The simultaneously
recorded pulse volume traces were processed
instantaneously to provide the pulse transit time (foot-
to-foot intervals) between right arm and right ankle,
and between left arm and left ankle, respectively.
Physiologically, the pulse travels from the heart to the
arms and ankles, separately, in opposite directions, and
not in a direction from the arm to the ankle. Therefore,
the time difference between the arm and ankle pulse
volume traces was assumed to correspond to the
different transit times required for the pulse to travel
from the heart to the arm and ankle, respectively. The
corresponding distance for the time difference was,
therefore, calculated as the difference between the
heart-to-ankle and heart-to-arm distances, and was
automatically estimated from height according to the
following regression equation: distance = 0.5934 =
height + 14.401. Thereafter, the right brachial-to-
right ankle pulse wave velocity (rbaPWV) was calculated
automatically as the distance divided by the transit
time between the right arm and right ankle, and left
brachial-to-left ankle pulse wave velocity (lbaPWV) as
the distance divided by transit time between the left
arm and left ankle. The right ankle-brachial index
(rABI) was directly calculated as the right ankle systolic
blood pressure divided by the higher brachial systolic
blood pressure, and the left ankle-brachial index (lABI)
was calculated as the left ankle systolic blood pressure
divided by the higher brachial systolic blood pressure.
Complete measurements of all pulse wave velocities
and ABIs were usually finished in less than 5 minutes.
Data analysis
In the present study, supine right-arm systolic and
diastolic blood pressures measured using the VP-1000
were used for all analyses. Because a long pulse transit
time is anticipated with resultant lower PWV in the
presence of peripheral arterial disease in the lower
extremities, we, therefore, selected the higher between
rbaPWV and lbaPWV as the representative baPWV for
indexing arteriosclerosis. Similarly, we selected the
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lower between rABI and lABI as the representative
ABI for indexing atherosclerosis.
The age- and sex-stratified normal reference values
(means and standard deviations) of the baPWV were
derived from a previous community survey performed
in Kinmen.20 High baPWV was defined as a value
higher than the upper limit of the normal reference
(mean plus 2 standard deviations). An ABI < 0.9 was
considered to indicate peripheral arterial disease and
the presence of systemic atherosclerosis.21
Clinical decision making
Because the participants as stable patients had been
followed up at the clinic for a long time, most of the
hypertensive patients had attained reasonably good
blood pressure control. Therefore, a high blood
pressure at clinic was usually not sufficient to up-titrate
the current antihypertensive medication unless it was
confirmed subsequently by a good record of 1-month
home blood-pressure monitoring or a 24-hour
ambulatory blood-pressure monitoring. With the
availability of baPWV and ABI at the point of care, the
cardiologist was able to make immediate decisions for
the study patients. Since high PWV in a hypertensive
patient might indicate inappropriate antihypertensive
treatment, the cardiologist, therefore, subjectively
decided to adjust the antihypertensive agents
accordingly to up-titrate the dosage or add another
antihypertensive medication if the baPWV was
obviously beyond the normal reference range. Different
classes of antihypertensive agents were chosen based
on the hypertension treatment guidelines1 because it
is, so far, generally accepted that diuretics, calcium
channel blockers, and angiotensin-converting enzyme
inhibitors share a similar ability to decrease arterial
stiffness in hypertensive patients.22
The antihypertensive dosage would also be down-
titrated if the systolic blood pressure at clinic was too low
and the baPWV was obviously within the normal range.
In a patient with occult peripheral arterial disease
defined by ABI < 0.9 but without symptoms, the
cardiologist would decide to intensify medical treatment
according to the treatment guidelines.23
Statistical analysis
Results are expressed as mean ( SD. Between-group
comparisons were performed using the paired t-test or
Chi-square test where appropriate. Within-group
comparisons were performed using the paired Student
t-test. Statistical significance was set at the p < 0.05
level. Multivariate logistic regression analysis was
performed to determine the predictors of high baPWV
and/or low ABI.
Results
Characteristics of the study population
A total of 124 patients were randomly selected for
rapid assessment of arteriosclerosis and atherosclerosis
from 586 stable patients in 12 study clinic services.
The selected and unselected patients were similar
except that the prescription of sulfonylurea was
significantly less common in the selected patients
(4.9% vs 11.4%, p < 0.05) (Table 1). The selected
patients were 83 men and 41 women with a mean age
of 67.4 years (range, 26–90 years). The most frequent
cardiovascular diagnosis was hypertension (70.7%),
followed by ischemic heart disease (56.9%).
Prevalence of high baPWV
Table 2 summarizes the anthropometric and
hemodynamic measurements provided by the VP-
1000 in 124 stable outpatients at the cardiology clinic.
Figure 1A displays the age- and sex-stratified prevalence
of high baPWV against the reference values obtained
from the previous community survey in Kinmen.
Overall, 24.2% of patients (16.9% of men and 39.0% of
women) under regular treatment had high baPWV.
Prevalence of low ABI
The age- and sex-stratified prevalence of low ABI
(ABI < 0.9) is shown in Figure 1B. The overall
prevalence of low ABI was 8.1% (7.2% in men and
9.8% in women). The prevalence of low ABI was very
low until the age of 70 years. Among the 9 patients
with low ABI, only 1 had symptoms of peripheral
arterial disease. The prevalence of occult peripheral
arterial disease was, therefore, 6.5%.
Characteristics of patients with high baPWV
and/or low ABI
Table 3 shows the comparison between patients with
high baPWV and/or low ABI and those with normal
baPWV and ABI. Patients with high baPWV and/or
low ABI were characterized by dominance of women,
lower prevalence of smoking, higher prevalence of
renal function impairment, and higher systolic blood
pressure. The independent predictors of high baPWV
and/or low ABI identified by multivariate logistic
regression analysis included female sex (odds ratio
7.69, 95% confidence interval 1.23–47.6, p = 0.029),
systolic blood pressure (odds ratio 1.07, 95% CI 1.03–
1.11, p = 0.001), and diabetes (odds ratio 3.91, 95%
confidence interval 0.98–15.72, p = 0.054). Age,
body mass index, triglycerides, high-density lipoprotein
cholesterol, and smoking status were not significant
predictors.
Arteriosclerosis and atherosclerosis in stable patients
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Table 1. Characteristics among selected, unselected, and all outpatients
Selected Unselected All
(n = 124) (n = 462) (n = 586)
Age, yr ((  SD) 67.4 ( 13.1 67.7 ( 13.9 67.7 ( 13.7
Sex, % male 66.7 59.6 61.1
Smoking, % 53.7 49.2 50.2
Hypertension, % 70.7 73.4 72.9
Ischemic heart disease, % 56.9 54.4 55.0
Valvular heart disease, % 16.3 19.2 18.6
Congenital heart disease, % 0.81 0.43 0.51
Stroke, % 1.63 3.02 2.73
Peripheral arterial disease, % 0.81 2.80 2.39
Carotid artery disease, % 4.07 6.05 5.63
Diabetes mellitus, % 20.3 23.97 23.21
Dyslipidemia, % 45.5 47.08 46.76
Atrial fibrillation, % 6.50 7.13 7.00
PTCA, % 4.87 5.83 5.63
CABG, % 4.07 5.18 4.94
Renal function impairment, % 7.3 5.4 5.8
Congestive heart failure, % 9.8 9.9 9.9
Angiotensin-converting enzyme inhibitors, % 36.6 35.9 36.0
Angiotensin II blockers, % 30.1 26.4 27.1
Calcium channel blockers, % 51.2 53.1 52.7
Diuretics, % 43.1 46.4 45.7
Antiplatelet agent, % 52.0 55.5 54.8
_-blocker, % 11.4 8.9 9.4
`-blocker, % 37.4 38.7 38.4
Statins, % 19.5 21.2 20.8
Fibrate, % 1.6 4.1 3.6
Sulfonylurea, % 4.9 11.4* 10.1
Biguanide, % 4.9 7.6 7.0
AGI, % 0 1.08 0.85
Insulin sensitizer, % 4.9 2.6 3.1
Insulin, % 0.8 1.0 1.0
*p < 0.05 as compared with the selected group. AGI = _-glucosidase inhibitor; CABG = coronary artery bypass graft; PTCA = percutaneous transluminal
coronary angiography.
Figure 1. Age- and sex-stratified prevalence of high baPWV (A) and ABI < 0.9 (B) in the 124 stable cardiology outpatients.
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Table 2. Summary of the anthropometric and hemodynamic parameters in the selected 124 stable cardiology outpatients
Variables Mean ( SD Range
Height, cm 162.9 ( 7.9 147–187
Weight, kg 63.3 ( 11.8 26–90
Waist, cm 84.6 ( 9.7 52–111
Heart rate, beats/min 68.3 ( 10.9 38–94
Right-arm SBP, mmHg 132.6 ( 18.8 78–190
Right-arm DBP, mmHg 74.5 ( 11.3 44–103
Left-arm SBP, mmHg 130.5 ( 19.2 74–179
Left-arm DBP, mmHg 73.9 ( 10.5 47–101
Right-ankle SBP, mmHg 146.5 ( 28.3 47–232
Right-ankle DBP, mmHg 73.3 ( 12.2 22–102
Left-ankle SBP, mmHg 144.2 ( 28.8 62–217
Left-ankle DBP, mmHg 72.0 ( 12.0 27–103
rABI 1.08 ( 0.10 0.60–1.32
lABI 1.07 ( 0.11 0.53–1.30
rbaPWV, m/s 1.8 ( 0.5 1.1–4.2
lbaPWV, m/s 1.8 ( 0.5 1.1–4.2
DBP = diastolic blood pressure; lABI = left ankle-brachial index; lbaPWV = left brachial-ankle pulse wave velocity; rABI = right ankle-brachial index;
rbaPWV = right brachial-ankle pulse wave velocity; SBP = systolic blood pressure.
Table 3. Comparison of patients with and without high baPWV and/or low ABI
High baPWV and/or low ABI Normal baPWV and ABI
p value
(n = 41) (n = 83)
Age, yr (( SD) 70.3 ( 12.5 65.6 ( 13.7 0.069
Age * 65 yr, % 70.7 62.7 0.374
Male, % 48.8 75.9 0.003
Total cholesterol, mg/dL (( SD) 146.9 ( 100.7 154.4 ( 91.3 0.676
Triglycerides, mg/dL (( SD) 101.6 ( 88.8 104.2 ( 97.2 0.887
HDL cholesterol, mg/dL (( SD) 32.8 ( 29.8 31.8 ( 27.2 0.860
LDL cholesterol, mg/dL (( SD) 135.2 ( 41.4 133.3 ( 40.9 0.836
LDL cholesterol >130 mg/dL, % 44.8 53.2 0.455
HDL cholesterol < 40 mg/dL, % 53.7 45.8 0.409
SBP, mmHg (( SD) 139.3 ( 22.5 127.7 ( 15.3 0.004
Hypertension, % 65.9 73.5 0.378
Diabetes, % 26.8 16.9 0.193
BMI * 25 kg/m2, % 23.3 38.2 0.150
Smoking, % 39.0 60.2 0.026
Renal function impairment, % 19.5 1.2 0.001
Angiotensin-converting enzyme inhibitors, % 39.0 36.1 0.755
Calcium channel blocker, % 58.5 48.2 0.278
Diuretics, % 51.2 38.6 0.180
Antiplatelet agent, % 48.8 54.2 0.569
_-blocker, % 14.6 9.6 0.408
`-blocker, % 29.3 41.0 0.205
Statins, % 19.5 19.3 0.975
Fibrate, % 2.4 1.2 0.608
Sulfonylurea, % 7.3 3.6 0.366
Biguanide, % 9.8 2.4 0.073
AGI, % 0.0 0.0 —
Insulin, % 2.4 0.0 0.153
Insulin sensitizer, % 2.4 6.0 0.381
ABI = ankle-brachial index; AGI = _-glucosidase inhibitor; BMI = body mass index; baPWV = brachial-ankle pulse wave velocity; HDL = high-
density lipoprotein; LDL = low-density lipoprotein; SBP = systolic blood pressure.
Arteriosclerosis and atherosclerosis in stable patients
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New clinical decisions
Based on the readily available reports of baPWV and
ABI at the clinic, the cardiologist judged to adjust the
medications in 56 patients (45.2%). In brief, new
classes of antihypertensive drugs were added in 33.9%,
original drugs up-titrated in 6% and down-titrated in
3% of patients.
As compared with subjects without adjustment of
medication, subjects with medication adjusted were
older (71.8 ( 10.2 vs 63.4 ( 14.6 years old, p = 0.0003)
and had higher systolic blood pressure (140 ( 17.6 vs
124.5 ( 16.8 mmHg, p < 0.0001) and baPWV (2.11
( 0.50 vs 1.65 ( 0.36 m/s, p < 0.0001).
Follow-up of baPWV and ABI
Of the 124 subjects enrolled for the survey, 47 received
repeat examination of baPWV and ABI during
subsequent visits. In the 22 patients who had their
antihypertensive medication adjusted (all up-titrated),
systolic blood pressure fell by 11 mmHg (from 145 (
13 mmHg at baseline to 134 ( 18 mmHg, p = 0.012),
baPWV fell by 0.2 m/s (from 2.3 ( 0.6 to 2.0 (
0.6 m/s, p = 0.001), while ABI did not change (from
1.07 ( 0.09 to 1.07 ( 0.09). In the 25 patients who
maintained previous antihypertensive medication, no
significant changes over systolic blood pressure
(from 129 ( 16 to 129 ( 17 mmHg), baPWV (from
1.9 ( 0.4 to 1.8 ( 0.3 m/s), and ABI (from 1.04 (
0.10 to 1.07 ( 0.10) were observed.
Discussion
The present study demonstrated that, in stable
cardiology patients on regular cardiovascular treatment,
the percentage of abnormally high baPWV and low
ABI may rise up to 24.2% and 8.1%, respectively. This
may imply that a substantial proportion of stable
patients who are followed up regularly in a cardiology
clinic are not receiving optimal treatment. This study
further suggests that the availability of rapid assessment
of arteriosclerosis and atherosclerosis at the point of
care may result in new decision making in a substantial
proportion of patients to achieve better care.
In our previous community-based survey in Kinmen,
the overall prevalence of high baPWV was 27.1% for
men and 25.4% for women.20 It is interesting to know
that the prevalence of high baPWV is similar in stable
patients regularly followed up at a cardiology clinic and
in residents of a community with limited medical
resources. On the other hand, the overall prevalence of
low ABI in Kinmen was very low (2.8% for men and
1.7% for women), as compared with that in the present
study. It is anticipated that many of the cardiology
patients had established cardiovascular disease and
significant arteriosclerosis and atherosclerosis. Not
surprisingly, they might have higher prevalence of low
ABI than community residents. However, it remains to
be demonstrated if high PWV can be completely
normalized with optimal current cardiovascular therapy.
Although both PWV and ABI can be measured
noninvasively and are commonly used in clinical or
community research, PWV has hardly been used
clinically and ABI is only indicated clinically as part of
assessments for patients with suspected peripheral
arterial disease. More importantly, measurements of
PWV and ABI by separate conventional methods are
usually time-consuming and performed at a vascular
laboratory distant from the outpatient clinic, and are,
therefore, not readily available for clinical decision
making during the same clinic visit.
Recently, a novel device (VP-1000) was developed
for simultaneous performance of pulse volume
recording over both arms and both ankles to
automatically generate the baPWV and ABI in less
than 5 minutes.18,24 With this technology, the indexes
for both arteriosclerosis and atherosclerosis are now as
conveniently available at the point of care (at an
outpatient clinic or on a ward) as an electrocardiogram
or a chest X-ray film.
Peripheral arterial disease is a progressive condition
associated with an elevated risk of heart attack and
stroke. Most cases are asymptomatic and the patients
face an increased risk of heart attack, stroke, and death,
whether or not the disease is symptomatic.25 The
identification of 8.1% asymptomatic patients with
peripheral arterial disease in the current study confirms
the disease to be a largely undiagnosed and undertreated
entity.25 More aggressive risk factor intervention along
with the administration of evidence-based medication26
is necessary to reduce future cardiovascular risk.25
Although there are clear guidelines for the
management of patients with peripheral arterial
disease,25,27 it remains empirical to adjust the treatment
protocol based on the findings of PWV. The decisions
to adjust medications for patients with abnormal
baPWV in this study were made solely according to the
senior cardiologist’s subjective judgment, due to
the lack of strict criteria or guidelines.22 In addition,
the impact of the new decisions on the outcomes
remains to be determined in future studies.
In conclusion, abnormal baPWV and ABI are not
uncommon in stable patients who are followed up
regularly at a cardiology clinic. Clinically, fast assessment
of arteriosclerosis and atherosclerosis may have a
potential for improving the quality of care.
H.M. Cheng, et al
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